

**LDLR EGF-AB domain H306Y, Myc-tagged**  
**Human, recombinant protein expressed in *E. coli*.**  
**Sterilized**  
**Cat# CY-R2343**

Amount: 50 µg (0.5 µg/µl x 100µl)

Lot:

**Introduction:**

PCSK9 binds to the LDL receptor *in vitro* through LDLR EGF-A domain. LDLR H306Y is derived from a mutant associated with one of familial hypercholesterolemia. It was reported that the EGF-AB domain H306Y-PCSK9 interaction is pH-independent, in addition, EGF-AB domain H306Y binds PCSK9 50-fold better at low pH.

**Product Description:**


Human LDLR EGF-AB domain H306Y, containing a C-terminal myc-tag is expressed in *E. coli*. and purified by GSH-column chromatography, subsequently sequence-specific protease digestion, followed by ion exchange chromatography. Binding capability of the LDLR EGF-AB domain H306Y, Myc-tagged to recombinant PCSK9 was confirmed by using CircuLex PCSK9-LDLR *in vitro* Binding Assay Kit (Cat# CY-8150). Unused LDLR EGF-AB domain H306Y, Myc-tagged should be stored at -70°C.

**Formulation:**

The LDLR EGF-AB domain H306Y, Myc-tagged is supplied frozen in 20 mM sodium phosphate buffer pH 7.2, 290 mM NaCl and 10 % glycerol.

**Purity:**

The LDLR EGF-AB domain H306Y, Myc-tagged is greater than 90 % pure as determined by SDS-PAGE analysis. Main impurities are ~30 kDa and ~70 kDa proteins derived from *E. coli*.

**Molecular Weight:**

**Storage:**

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, AVOID REPEATED HANDLING AND MULTIPLE FREEZE/THAW CYCLES.

**Stability:**

Unopened vial at -70 °C, for 1 year after delivery.

**General References:**

1. Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, Cummings RT, Cubbon RM, Lo Surdo P, Calzetta A, Noto A, Baysarowich J, Mattu M, Talamo F, De Francesco R, Sparrow CP, Sitlani A, Carfi A. (2009) *J Biol Chem.* 284: 1313-23
2. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M (2003) *Proc Natl Acad Sci USA* 100:928–933
3. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003) *Nat Genet* 34:154–156
4. Leren TP (2004) *Clin Genet* 65:419–422
5. Allard D, Amsellem S, Abifadel M, Trillard M, Devillers M, Luc G, Krempf M, Reznik Y, Girardet JP, Fredenrich A, et al. (2005) *Hum Mutat* 26:497.
6. Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH (2006) *N Engl J Med* 354, 1264–1272
7. Berge KE, Ose L, Leren TP (2006) *Arterioscler Thromb Vasc Biol* 26:1094–1100
8. Maxwell KN, Breslow JL (2004) *Proc Natl Acad Sci USA* 101:7100–7105
9. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD (2005) *Proc Natl Acad Sci USA* 102:5374–5379
10. Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., and Horton, J. D. (2006) *J. Clin. Investig.* 116, 2995–3005
11. Cameron, J., Holla, O. L., Ranheim, T., Kulseth, M. A., Berge, K. E., and Leren, T. P. (2006) *Hum. Mol. Genet.* 15, 1551–1558
12. Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., and Hobbs, H. H. (2007) *J. Biol. Chem.* 282, 18602–18612
13. Hyock Joo Kwon, Thomas A. Lagace, Markey C. McNutt, Jay D. Horton, and Johann Deisenhofer (2008) *Proc Natl Acad Sci USA* 105: 1820–1825
14. Matthew J. Bottomley et al. (2009) *J. Biol. Chem.* 284, 1313-1323
15. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. (2009) *J. Biol. Chem.* 284, 10561-70

**Related Products:**

- \* CircuLex Mouse/Rat PCSK9 ELISA Kit: Cat# CY-8078
- \* CircuLex Human PCSK9 ELISA Kit: Cat# CY-8079
- \* CircuLex PCSK9-LDLR in vitro Binding Assay Kit: Cat# CY-8150
- \* Anti-Human PCSK9 prodomain monoclonal antibody (KS-3C8): Cat# CY-M1032
- \* Anti-Human PCSK9 monoclonal antibody (KS-4H12): Cat# CY-M1033
- \* PCSK9 Wild Type in culture medium: Cat# CY-R2310
- \* PCSK9 Δ(33-53) / Wild Type in culture medium: Cat# CY-R2320
- \* PCSK9 D374Y in culture medium: Cat# CY-R2311
- \* PCSK9 Δ(33-53) / D374Y in culture medium: Cat# CY-R2321
- \* PCSK9 Wild Type/Δ53 in culture medium: Cat# CY-R2320
- \* PCSK9 Wild Type: Cat# CY-R2330
- \* PCSK9 D374Y: Cat# CY-R2331
- \* PCSK9 R194A: Cat# CY-R2333

- \* LDLR EGF-AB domain: Cat# CY-R2340
- \* LDLR EGF-AB domain, Myc-tagged: Cat# CY-R2341
- \* LDLR EGF-AB domain H306Y: Cat# CY-R2342
- \* LDLR EGF-AB domain H306Y, Myc-tagged: Cat# CY-R2343

**PRODUCED BY**

CycLex Co., Ltd.  
1063-103 Terasawaoka  
Ina, Nagano 396-0002  
Japan  
Fax: +81-265-76-7618  
e-mail: [info@cyclex.co.jp](mailto:info@cyclex.co.jp)  
URL: <http://www.cyclex.co.jp>

CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.